Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS)
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
036
The Comprehensive Analysis Platform To Understand, Remedy and Eliminate Amyotrophic Lateral Sclerosis (CAPTURE ALS) will pool resources and talent in Canada to advance our understanding of the biological basis of ALS and address its heterogeneity.
ALS drug discovery has been hampered by the complexity of the disease, clinical heterogeneity and rare disease status. Key advances will be expedited through multisite, multidisciplinary collaborations and the sharing of data and materials. CAPTURE ALS will leverage and expand the existing clinical network and infrastructure developed by the Canadian ALS Neuroimaging Consortium (CALSNIC) to provide the most comprehensive picture of a person living with ALS. It will be driven academically initially through four existing ALS centres in Edmonton, Toronto, Montreal, and Quebec City, with the vision for subsequent expansion to other clinics in the future.
CAPTURE ALS will provide the infrastructure and tools to enable the collection, storage, analysis and dissemination of standardized, longitudinal, multi-dimensional data and biosamples from patients with ALS, related disorders, and healthy controls. Participants will be followed prospectively to collect detailed clinical, neurocognitive, speech, and imaging data, accompanied by serum, plasma, peripheral blood mononuclear cells, cerebrospinal fluid, urine, and postmortem material. There will be a strong focus on patient engagement, garnering the advice of a Patient Partner Advisory Council (PPAC) through the design and execution process.  
The rich datasets and samples collected through this platform will be used to develop and validate novel ALS biomarkers and enable the multidimensional stratification of ALS patients based on clinical phenotype, and imaging, genetic and cellular characteristics. Operating through Open Science principles, data and samples will be available to investigators and industry partners.

CAPTURE ALS will contribute to global efforts to expedite ALS research, and provide hypothesis and data driven insights into disease mechanisms and clinical heterogeneity.
Authors/Disclosures
Sanjay Kalra, MD (University of Alberta)
PRESENTER 		The institution of Dr. Kalra has received research support from Brain Canada Foundation. The institution of Dr. Kalra has received research support from Biogen.
No disclosure on file
Nicolas Dupre, MD, FÂ鶹´«Ã½Ó³»­ (CHU de Quebec - U Laval) Dr. Dupre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea Therapeutics Canada. The institution of Dr. Dupre has received research support from ARSACS Foundation. The institution of Dr. Dupre has received research support from CHUdeQuebec Foundation.
Alan Evans, PhD (McGill University) Dr. Evans has received personal compensation for serving as an employee of biospective. Dr. Evans has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for biospective.
Angela L. Genge, MD (Mcgill University) Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
No disclosure on file
Wendy Johnston, MD, FRCP(C), FÂ鶹´«Ã½Ó³»­ (Universtiy of Alberta) Dr. Johnston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Johnston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Inc.. Dr. Johnston has a non-compensated relationship as a Board Member with ALS Canada that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Johnston has a non-compensated relationship as a Chair with Canadian ALS Clinical Research Group that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
David C. Taylor, MD No disclosure on file
No disclosure on file
Lorne H. Zinman, MD Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, MTP, AB Science, Cytokinetics, Amylyx. Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx.
No disclosure on file